The Supreme Court of the United States on Friday, January 13, 2017 granted a review of the Amgen v. Sandoz patent dispute case in regards to the FDA licensing of “biologics” (which are products such as viruses, vaccines as well as antitoxins).
SCOTUS GRANTS REVIEW OF AMGEN V SANDOZ
Mahogany wooden gavel on glossy wooden table, USA flag in the background.